23 Feb Avectas
Michael Maguire, Ph.D., CEO
Avectas is a cell engineering technology business focused on improving the cost, manufacturing, and patient outcomes for the next generation of cellular therapies. Avectas is developing a unique cell engineering platform, SOLUPORE™, to enable the ex vivo manufacture of gene modified cell therapy products. SOLUPORE™ is a patented, non-viral, cell engineering technology that permeabilizes the target cell membrane and allows efficient transfer of cargo into cells whilst retaining very high levels of cell viability and functionality.